跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCT2071210051
JPRN-jRCT2071210051招募中2 期

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of AB-106 in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

akayama Tomoko0 个研究点目标入组 20 人开始时间: 2021年8月13日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable（—）
性别
All

入选标准

  • •1. Patient age 18 years and over (or 20 years and over as required by local regulations).
  • •2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic
  • •NSCLC (cohorts 1-3) or other solid tumors (cohort 4).
  • •3. Evidence of ROS1 fusion in tumor tissue determined by molecular assays as performed in Clinical Laboratory Improvement Amendments (CLIA)-certified or locally equivalent laboratories. Sufficient tumor tissue is required for performing confirmatory ROS1 fusion testing at the designated central laboratories.
  • •4. Patients in cohort 1 must have an archival tumor tissue specimen available and collected prior to enrollment. If archival tumor tissue is unavailable, then a mandatory fresh biopsy must be performed. For patients in cohort 2, a mandatory fresh biopsy is required before enrollment even if archival tumor tissue is available. For cohorts 3-4, either an archival tumor tissue or a fresh tumor sample must be available before enrollment.
  • •5. Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed; the use of seizure prophylaxis is allowed as long as patients are taking non enzyme-inducing anti-epileptic drugs (non-EIAEDs). If corticosteroid treatment is required, it should be on stable or decreasing dose of 10 mg prednisone equivalent or less. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment at least 14 days before enrollment and be clinically stable.
  • •6. The patient is either ROS1 TKI treatment naive, or treated with prior ROS1 TKI(s):
  • •Cohort 1: Systemic chemotherapy naive or pretreated with one prior line of chemotherapy, but never treated with any ROS1 TKI
  • •Cohort 2: Pretreated with one prior ROS1 TKI which is locally marketed, AND pretreated with <=1 prior line of chemotherapy
  • •Cohort 3: Pretreated with >=2 prior ROS1 TKIs, AND pretreated with <=2 prior lines of chemotherapy
  • •Cohort 4: Systemic chemotherapy naive or pretreated with <=2 prior lines of chemotherapy, but never treated with any ROS1 TKI.
  • •7. At least one extracranial measurable unirradiated lesion per RECIST 1.1 assessed by investigators.
  • •8. Eastern Cooperative Oncology Group Performance Status: 0 or 1.
  • •9. Patient with a life expectancy 12 weeks based or more on the judgement of investigators.
  • •10. Patients with adequate organ function meeting the following criteria:
  • •a) AST and ALT: <=3 x upper limit of normal (ULN) (or <=5 x ULN, in case of liver abnormalities due to liver
  • •metastases)
  • •b) Serum total bilirubin: <=1.5 x ULN
  • •c) Absolute neutrophil count: >=1,500 per microliter
  • •d) Platelet count: >=100,000 per microliter
  • •e) Hemoglobin: >=9.0 g per deciliter
  • •f) Serum creatinine: <=1.5 x ULN.
  • •11. Males and/or females who meet any of the following criteria:
  • •a) For males (irrespective of surgical sterilization [vasectomy]): agree to use effective contraception methods during the study intervention period and for at least 90 days after the last dose of investigational drug or agree with complete abstinence;
  • •b) For females be post-menopausal for at least one year prior to screening or be documented surgically sterilized. Women of childbearing potential (WOCBP) must agree to use two concurrent effective methods of contraception or agree with complete abstinence from sexual intercourse since the informed consent until 90 days after the

排除标准

  • •1. Investigational agent or anticancer therapy within 2 weeks (or 5 half-lives of the compound, whichever is longer) prior to study enrollment. In addition, no concurrent anticancer therapy is permitted.
  • •2. Previously treated with immuno-oncology (IO) including immune checkpoint inhibitors within 12 weeks before enrollment.
  • •3. Major surgery within 4 weeks prior to enrollment.
  • •4. Radiation therapy with a limited field for palliation within 1 week of the first dose of study treatment.
  • •5. Toxicities due to prior therapy are unresolved to <= CTCAE 5.0 Grade 1 except for AEs not constituting a safety risk to the patient based on the judgment of investigators.
  • •6. Patients with spinal cord compression caused by tumor and/or cancerous meningitis.
  • •7. History or evidence of interstitial fibrosis or interstitial lung disease or pneumonitis.
  • •8. Any gastrointestinal disorders that may affect absorption of oral medications.
  • •9. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  • •10. Clinically significant cardiovascular diseases within 3 months prior to the first dose of
  • •investigational drug: myocardial infarction, severe/unstable angina,coronary/peripheral
  • •endovascular treatment, heart failure or cerebrovascular disorder including transient ischemic attack.
  • •11. Ongoing cardiac dysrhythmias of > CTCAE 5.0 Grade 2, uncontrolled atrial fibrillation of
  • •any grade, or QT interval corrected for heart rate (QTc) interval >470 milliseconds (female) or QTc interval >450 milliseconds (male), or symptomatic bradycardia <45 beats per minute.
  • •12. Pregnancy or lactation.
  • •13. Use of food or drugs that are known potent cytochrome P450 3A4/5 (CYP3A4/5) inhibitors or inducers or P-glycoprotein inhibitors or inducers within 14 days prior to the first dose of study treatment.
  • •14. Patients with other severe medical or mental diseases in whom the risk is increased by the participation to the study or treatment with investigational drug in the opinion of the investigator.

研究者

发起方
akayama Tomoko

相似试验

尚未招募
2 期
To evaluate if NRC-2694-A and Paclitaxel is safe and will reduce the tumor size for recurrent/metastatic Head and Neck cancer patients who fail to respond ICI therapy.
CTRI/2023/12/060746ATCO Pharma Limited
已完成
2 期
A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell LymphomaRefractory or relapsed (relapse after transplant or relapse after medication in patients ineligible for transplant) diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), transformed follicular lymphoma (TFL) or High-grade B cell lymphoma
JPRN-jRCT1080223858Gilead Sciences K.K.10
进行中（未招募）
不适用
A clinical study of a new drug called E7080 for patients with cancer of the womb that has spread to other parts of the body after having one platinum based chemotherapy. The patients know they are receiving the drug. The study is being done in different countries and the safety and effectivenes of E7080 have already been studied in other cancer patients.
EUCTR2009-016858-41-HUEisai Ltd.130
进行中（未招募）
不适用
A clinical study of a new drug called E7080 for patients with cancer of the womb that has spread to other parts of the body after having one platinum based chemotherapy. The patients know they are receiving the drug. The study is being carried out in different countries and the safety and effectivenes of E7080 have been studied in other cancer patients.
EUCTR2009-016858-41-BEEisai Ltd.130
进行中（未招募）
不适用
An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapynresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapyMedDRA version: 14.0Level: PTClassification code 10014740Term: Endometrial cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10014736Term: Endometrial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10014734Term: Endometrial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10014741Term: Endometrial cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-016858-41-BGEisai Ltd.130